Newer lactation information on injectable semaglutide is more reassuring than older no data statements, but the evidence is still limited and your babys age, feeding pattern, and your medical reason for the medication matter
We dont have any evidence that low-dose, intermittent use of GLP-1s provides meaningful or sustained weight loss or broader health benefits
A., Jimnez-Murcia, S., & Fernandez-Aranda, F
High reproducibility was indicated by a median coefficient of variation 95%) was characterized with a molecular mass of 1,178.5/[M+4H]4+ and 1,570.8/[M+3H]3+, which is consistent with the theoretically calculated molecular weight of 4,710.1 with formula C 214 H 315 N 49 O 69 S
Inhibition of SGLT-1 in the small intestine causes more glucose transport to the distal intestine and colon, resulting in greater fermentation of glucose to SCFAs by luminal bacteria and increased sustained release of GLP-1 in the distal intestine [174] (Fig
These require prompt medical evaluation: Pancreatitis: Pancreatitis has been reported in individuals using GLP-1 receptor agonists